Business
Portfolio news - Exscientia
Portfolio news - Exscientia.
About this update from Frontier Ip Group Plc
[{"type":"text","content":"\n \nRNS Number : 4952B Frontier IP Group plc 31 January 2020 \n\nRNS Reach\nAIM: FIPP\n31 January 2020\n \n \nFrontier IP Group Plc\n(\"Frontier IP\" or the \"Group\")\n \nPortfolio news - Exscientia: world's first clinical trials of new drug candidate created by Artificial Intelligence (\"AI\") started in joint development with Sumitomo Dainippon Pharma \n \n \nFrontier IP, a specialist in commercialising university intellectual property, is pleased to note that portfolio company Exscientia (\"Exscientia\" or the \"Company\"), a world leader in AI-driven drug discovery, has announced the first AI-created drug to enter clinical trials in a joint development with Sumitomo Dainippon Pharma. \n \nA phase I clinical study of the drug candidate DSP-1181, designed to treat obsessive-compulsive disorder as an initial indication, has started in Japan. \n \nExscientia's other partnerships include collaborations with Bayer AG, Celgene, Sanofi, GT Apeiron, Rallybio and Evotec. Frontier IP currently holds a 3.25 per cent stake in the Company. \n \n \nExscientia statement in full:\n \nSumitomo Dainippon Pharma and Exscientia Joint Development New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Trial\n \nSumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka, Japan, Representative Director, President and CEO: Hiroshi Nomura) and Exscientia Ltd. (Headquarters: Oxford, UK; CEO: Andrew Hopkins) announce that a phase I clinical study of DSP-1181, that was created using Artificial Intelligence (AI), has been initiated in Japan for the treatment of obsessive-compulsive disorder as an initial indication.\n \nDSP-1181 was created through the joint research by Sumitomo Dainippon Pharma and Exscientia, with Sumitomo Dainippon Pharma providing its experience and knowledge in monoamine GPCR drug discovery and Exscientia applying its Centaur Chemist™ Artificial Intelligence (AI) platform for drug discovery. This project was delivered by the strong synergy of the joint research, requiring less than 12 months to complete the exploratory research phase, just a fraction of the typical average of 4.5 years using conventional research techniques. ref)\n \nDSP-1181 is being progressed as a long-acting and potent serotonin 5-HT1A receptor agonist, and its phas...